Treatment persistence among bio-naïve patients with Crohn’s disease initiated on ustekinumab or adalimumab

References

• Crohn’s & Colitis Foundation of America. The facts about inflammatory bowel diseases; 2014 [cited 2020 Dec 11]. Available from: http://www.crohnscolitisfoundation.org/assets/pdfs/updatedibdfactbook.pdf
   Google Scholar
• Ye Y, Manne S, Bennett D. 654 Prevalence of inflammatory bowel disease in the U.S. adult population: recent estimates from large population-based national databases. Am J Gastroenterol. 2018;113(Supplement): S373–S374.
   Google Scholar
• Floyd DN, Langham S, Severac HC, et al. The economic and quality-of-life burden of Crohn’s disease in Europe and the United States, 2000 to 2013: a systematic review. Dig Dis Sci. 2015;60(2):299–312.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160(7):2496–2508.
   PubMed Web of Science ®Google Scholar
• Khan S, Rupniewska E, Neighbors M, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507.
   PubMed Web of Science ®Google Scholar
• Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States. PLoS One. 2017;12(4):e0175099.
   PubMed Web of Science ®Google Scholar
• Teeple A, Sah J, Mallampati R, et al. Persistence, dosing, and other treatment patterns among Crohn’s disease patients initiating biologics in United States. Crohns Colitis. 2021;3(4):360.
   Google Scholar
• Macaluso FS, Orlando A, Cottone M. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease. Expert Opin Biol Ther. 2019;19(2):89–98.
   PubMed Web of Science ®Google Scholar
• Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200–2211.
   PubMed Web of Science ®Google Scholar
• Irving PM, Sands BE, Hoops T, et al. OP02 ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn’s disease: the SEAVUE study. J Crohns Colitis. 2021;15(Supplement_1):S001–S002.
   PubMed Web of Science ®Google Scholar
• de Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inform. 2015;22(3):368–373.
   PubMedGoogle Scholar
• Bernstein CN, Blanchard JF, Rawsthorne P, et al. Epidemiology of Crohn’s disease and ulcerative colitis in a Central Canadian province: a population-based study. Am J Epidemiol. 1999;149(10):916–924.
   PubMed Web of Science ®Google Scholar
• Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn’s disease and ulcerative colitis. Am J Gastroenterol. 2011;106(12):2133–2142.
   PubMed Web of Science ®Google Scholar
• Burden AM, Paterson JM, Gruneir A, et al. Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data. Pharmacoepidemiol Drug Saf. 2015;24(1):67–74.
   PubMed Web of Science ®Google Scholar
• Walsh JA, Cai Q, Lin I, et al. Treatment persistence and adherence among patients with psoriatic arthritis who initiated targeted immune modulators in the US: a retrospective cohort study. Adv Ther. 2021;38(5):2353–2364.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. STELARA® (ustekinumab) injection, for subcutaneous or intravenous use: highlights of prescribing information; 2020. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf
   Google Scholar
• US Food and Drug Administration. HUMIRA® (adalimumab) injection, for subcutaneous use: highlights of prescribing information; 2021. Available from: https://www.rxabbvie.com/pdf/humira.pdf
   Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simulat Comput. 2009;38(6):1228–1234.
   Web of Science ®Google Scholar
• Ding Z, Obando C, Muser E, et al. Real-world persistence, maintenance dosing, and pre-post corticosteroid and opioid use among Crohn’s disease patients with prescription claims for ustekinumab in the USA. Drugs Real World Outcomes. 2021;8(4):565–575.
   PubMedGoogle Scholar
• Chien TH, Puig A, Khuong T, et al. An Australian real-world study of treatment persistence of ustekinumab in Crohn’s disease. Biologics. 2021;15:237–245.
   PubMed Web of Science ®Google Scholar
• Moens A, Alsoud D, Verstockt B, et al. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center. Eur J Gastroenterol Hepatol. 2022;34(10):1015–1020.
   PubMed Web of Science ®Google Scholar
• Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–1427.
   PubMed Web of Science ®Google Scholar
• Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413–1432.
   PubMed Web of Science ®Google Scholar
• Glassner K, Wang L, Ezeana C, et al. S0707 the use of combination vedolizumab and ustekinumab in Crohn’s disease: a retrospective cohort study. Am J Gastroenterol. 2020;115:S355.
   Google Scholar
• Ehrenberg R, Griffith J, Theigs C, et al. Dose escalation assessment among targeted immunomodulators in the management of inflammatory bowel disease. J Manag Care Spec Pharm. 2020;26(6):758–765.
   PubMed Web of Science ®Google Scholar
• Feagins LA, Waljee A, Hou JK, et al. Incidence of and predictors for early discontinuation of biological therapies in veteran patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(8):1434–1439.
   PubMed Web of Science ®Google Scholar